{'fraction_non_alphanumeric': 0.03621399176954732, 'fraction_numerical': 0.027160493827160494, 'mean_word_length': 5.268041237113402, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open‐Access ALS clinical trials database

Introduction: Urate has been identified as a predictor of amyotrophic lateral sclerosis (ALS) survival in some but not all studies. Here we leverage the recent expansion of the Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) database to study the association between urate levels and ALS survival. Methods: Pooled data of 1,736 ALS participants from the PRO‐ACT database were analyzed. Cox proportional hazards regression models were used to evaluate associations between urate levels at trial entry and survival. Results: After adjustment for potential confounders (i.e., creatinine and body mass index), there was an 11% reduction in risk of reaching a survival endpoint during the study with each 1‐mg/dL increase in uric acid levels (adjusted hazard ratio 0.89, 95% confidence interval 0.82–0.97, P < 0.01). Discussion: Our pooled analysis provides further support for urate as a prognostic factor for survival in ALS and confirms the utility of the PRO‐ACT database as a powerful resource for ALS epidemiological research. Muscle Nerve 57: 430–434, 2018